leisure time -WSS

leisure time

author：focus 2025-09-30 09:31:14 - browse：42

Are biotech’s dog days over? What’s a PIPE? And what can unseat Wegovy?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it’s such a good idea. We also discuss a banner month for biotech stocks and the latest twist in obesity research.

For more on what we cover, here’s more on PIPEs; here’s the news from Viking Therapeutics; here’s the latest in MASH; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

leisure time

WSS

Abridge raises $150m as clinical notes automation market heats up

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

In 'major milestone,' FDA approves first cell therapy for solid tumors

Will the IRA bring competition to the biologics market?

New study raises questions about niacin and heart health

Hospitals consider fixing cancer drug shortages on their own

focus

leisure time

knowledge

At least 13 dead in Texas as scorching temps continue

In 'major milestone,' FDA approves first cell therapy for solid tumors

Alkermes shareholders re

Medicare Advantage enrollment hits roughly 33.4 million

Medical leaders decry Supreme Court decision on affirmative action

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Continuity nursing helped my family in our darkest PICU moments

FDA warns medical device makers about rise in fabricated data

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

explore

New CMS data security rules will hurt Medicare, Medicaid research

Reporting on presidential health from Reagan to Trump and Biden

Diverse clinical trials: Why aren’t we there yet?

Congress may force more Covid

White House touts steps to stem shortages of cancer treatments

Measles policy set amid Florida outbreak alarms vaccine proponents

focus

leisure time

entertainment

focus